PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Lipella Pharmaceuticals Inc. (LIPO)
Company Research
Source: GlobeNewswire
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit. Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023. With these nods from the FDA, the company is on track to deliver two safe and effective treatments to cancer survivors, with a third therapeutic in its pipeline. Dr. Kaufman remarked, “Orphan drug development can often be more profitable, entail lower risk and result in faster time to approval than non-orphan therapeutics. Our strategy involves leveraging the 505(b)(2) pathway which we believe will lower cost and allow for a faster approval process by allowing us to bypass Phase 1 trials and immediately i
Show less
Read more
Impact Snapshot
Event Time:
LIPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIPO alerts
High impacting Lipella Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
LIPO
News
- Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseGlobeNewswire
- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) is now covered by analysts at Maxim Group. They set a "buy" rating and a $2.00 price target on the stock.MarketBeat
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024GlobeNewswire
LIPO
Sec Filings
- 4/19/24 - Form 8-K
- 4/12/24 - Form 8-K
- 3/19/24 - Form 4
- LIPO's page on the SEC website